Association of low-energy femoral shaft fractures and bisphosphonate use

Orthopedics

Volumn 35, Issue 1, 2012, Pages

  Fowler, John R ^a   Craig, Matthew R ^a,b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE RADIOGRAPHY; CONTROLLED STUDY; DIAPHYSIS; DISEASE ASSOCIATION; DRUG USE; FALLING; FEMALE; FEMUR SHAFT FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DIPHOSPHONATES; DRUG TOXICITY; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; OSTEOPOROTIC FRACTURES; PENNSYLVANIA; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84855678500     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20111122-06     Document Type: Article

References (14)

1. Rodan GA, Reszka AA. Osteoporosis and bisphosphonates. J Bone Joint Surg Am. 2003; 85(suppl 3):8-12. (Pubitemid 36951112)
2. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005; 87(7):1609-1618. (Pubitemid 40917766)
3. Gates BJ, Sonnett TE, Duvall CA, Dobbins EK. Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother. 2009; 7(6):293-323.
4. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002; 166(11):1426-1430. (Pubitemid 34539362)
5. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-1541. (Pubitemid 26411651)
6. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155.
7. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009; 91(11):2556-2561.
8. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007; 13(6):485-489. (Pubitemid 351206686)
9. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89(3):349-353. (Pubitemid 46563912)
10. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy [published online ahead of print January 28, 2008]? Injury. 2008; 39(2):224-231.
11. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-1306. (Pubitemid 351439247)
12. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study [published online ahead of print December 9, 2008]. Osteoporos Int. 2009; 20(8):1353-1362.
13. Neviaser AS, Lane JM, Lenart BA, Edobor- Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-350. (Pubitemid 351630250)
14. Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy [published online ahead of print February 6, 2009]. Clin Orthop Relat Res. 2009; 467(7):1921-1926.